Top Tech Companies (83)
Don't see your company?
Create a company profile
At Akili, we’re creating personalized digital therapeutics engineered to directly improve cognitive impairments. Our medicines look and feel like high-end interactive action video games but, unlike typical video games, they are informed by decades of neuroscience and built with proprietary technology developed to target and treat cognitive impairments at their specific sources in the brain. Not only is our medicine designed to target the areas of your brain that need it most, it’s designed specifically for you, adapting based on your individual needs.
Elemental Machines is helping scientists improve experimental reproducibility and accelerate scientific discovery. With a new suite of connected products that harness the power of cloud-based software, machine learning and distributed sensors, Elemental Machines is giving scientists and researchers an easy, powerful and cost-effective solution fo
CELLINK is a global leader in developing and delivering life-science solutions, equipping hundreds of labs and thousands of scientists worldwide with cutting-edge technologies that fuel groundbreaking scientific breakthroughs. With a commitment to quality and innovation, our bioprinters, imaging systems and bioinks have contributed to revolutionary advancements in academic and clinical medicine. We strive to push the limits of what is possible in regenerative medicine and pharmaceutical development, inspiring and empowering collaborators to expand their horizons and overcome any challenge they face. We are striving to enable scientists around the globe that are doing groundbreaking research.
At Scipher, we are relentlessly driven to solve one of healthcare’s biggest challenges and improve patient health outcomes. Scipher’s mission is to match each autoimmune patient with their most effective therapy. Each year, hundreds of billions of dollars are wasted prescribing drugs of limited clinical benefit to patients, even though there are often effective alternative therapies available. We believe there is a better way.
Our team develops simple, efficient procure-to-pay solutions for biotech research organizations as they develop life-saving therapies for the world's most serious health problems. Prendio is proud to play a small part in this important healing mission.
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics. Built upon academic research in the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University, Clasp is backed by prominent life sciences investors including Catalio Capital Management, Third Rock Ventures and Novo Holdings. The company was launched in March 2024 and is based in Cambridge, MA and Rockville, MD.
AG Mednet’s technology solves critical problems for the pharmaceutical, biotechnology and medical device markets. As the leading partner for endpoint/adverse event adjudication and imaging data collection and QC, we work with the world’s top pharmaceutical companies and CROs.
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 61,000 staff across a network of over 1,000 independent companies in 59 countries, operating 940 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 33% each year (in compound average) to reach €6.7 billion in 2021.
Founded in 2022 and headquartered near Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations.
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies. Our team includes world-class molecular and synthetic biologists, protein engineers and gene therapy scientists working alongside software engineers, data scientists, and AI and machine learning experts. As we create AI-powered gene therapies that enhance the life-changing potential of gene therapies for millions of patients, we believe the future is within reach. Gene vectors are the key for enabling gene therapies to reach a wider range of diseases and patients. Success in gene therapy relies on the vector’s ability to safely and precisely deliver a gene payload to the intended target cells and tissues. The efficacy of gene therapies, however, is currently limited by the roster of naturally occurring vectors, which are not optimized for disease treatment. To solve this problem and realize the full potential of gene therapy, Dyno is building its portfolio of proprietary AAV vectors, and working with licensing partners to build targeted AAV vectors enabling treatments in a wide range of disease areas and indications.
We are a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. We make a positive difference to millions of people’s lives every day. Our constant curiosity and specialist approach drive our partnerships and bring new ideas to life. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. We trust in the talent and passion of our curious minds; that's why we're creating an environment where they can unleash their potential and meet their individual needs. We foster a culture where everyone feels welcome. Our work is fueled by our belief in science as a force for good. We work to enhance the human experience and create more joyful and sustainable ways to live. We are here for people at every step, helping to create, improve and prolong life. We deliver personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. We empower the scientific community. Our tools, services and digital platform make research simpler, more exact, and help to deliver breakthroughs more quickly. Our solutions accelerate access to health by assuring tests are accurate and the medicine we take can be trusted. We are the company behind the companies advancing digital living. Our science sits inside technologies that are changing the way we access, store, process, and display information. Our innovations are unlocking the power and potential of data to open new possibilities to transform life on Earth as we know it. We believe that scientific exploration and responsible entrepreneurship are key to technological advances that benefit us all. This is how Merck has thrived since 1668. And we will continue to push the boundaries of possibility to create opportunities for everyone. This is what drives us. This is what we work for. This is our future. We are curious minds dedicated to human progress.
High Touch Group is a privately held consultancy that helps science, engineering, and technology clients market existing products and services, showcase their value, develop and launch new products, engage with investors, generate leads, and drive revenue. We keep the science and make it exciting.
Intelon Optics, Inc. is a medical device company focusing on the development and commercialization of the Brillouin Optical Scanner System, or BOSS™, a technology that enables revolutionary, point-by-point biomechanics imaging of eye structures extending from the front of the eye, or the cornea, to the back of the eye, empowering eye care professionals to make treatment decisions with confidence based on biomechanical tissue properties.
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
Medidata is leading the digital transformation of life sciences with the world's most-used platform for clinical development, commercial and real-world data. Powered by artificial intelligence and delivered by #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies and academic
At PathAI our mission is to improve patient outcomes with AI-powered technology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
Applied Pathology Systems is a Histopathology laboratory in Greater Boston that provides cutting-edge histology services and has a strong reputation for preparing, embedding, staining, and interpreting tissue sections. The laboratory is CLIA certified and led by experienced histologists working under the guidance of US board-certified pathologists. APS offers general histology, immunohistochemistry, digital imaging & analysis, pathology evaluation, and surgical pathology consultations. Human and veterinary board-certified pathologists specialize in Gastroenterology and Dermatology with years of subspeciality training.
